agree, the first clearance was pretty much a "fluffer" to get things ready for the reverse split. Ecoli test is great and all but isnt going to be as huge revenue generating product here in the US as to say a country like China where Ecoli is more of an issue. The Staph one coming up post RS. (Im thinking 1st week of April (guess))is going to generate alot more revenue and will be used alot more than the shinga test. The 2017 pre surgery one in 2017 will be massive for this company. IMO post split will be brough down pretty hard. They will release that 2nd one towards the end of the 10 day pps nasdaq requirments to gain another boost to make sure they achive it.